Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 23, Issue 1, 2001, Pages 41-45

  Ley, L M ^a   Stahlheber Dilg, B ^a   Sander, P ^a   Huber, R ^a   Mascher, H ^a   Lucker P W ^a  

^a Inst Klin Pharmakologie Bobenheim   (Germany)

Author keywords

Crushed pantoprazole tablet; Enteric coated tablet; Healthy volunteers; Magaldrate; Relative bioavailability; Riopan ; Sodium hydrogencarbonate

Indexed keywords

BICARBONATE; MAGALDRATE; PANTOPRAZOLE;

ADULT; ARTICLE; BIOEQUIVALENCE; BURN; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; MALE; NORMAL HUMAN;

EID: 0034970119     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2001.23.1.619179     Document Type: Article

References (29)

1. Risk factors for gastrointestinal bleeding in critically ill patients
2. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients
3. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient
4. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage
5. Comparison of 24-H control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer
6. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcers
7. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates
8. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate
9. Review article: The continuing development of proton pump inhibitors with particular reference to pantoprazole
10. Oral pantoprazole for erosive esophagitis: A placebo-controlled, randomized clinical trial
11. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients
12. Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease
13. Pantoprazole: A pharmacological and clinical profile
14. Cytoprotective and antiulcer activities of the antacid magaldrate in the rat
15. Effects of magaldrate on circadian profile of gastric juice pH in medical intensive care patients
16. The effects of sodium bicarbonate ingestion on exercise performance
17. Comparison of oral sodium compounds for correction of acidosis
18. +-ATPase inhibitor (BY1023/SK&F96022) and is sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up
19. Presentation of results from bioequivalence studies
20. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients
21. Pharmacokinetics of pantoprazole in man
22. Pantoprazole in the elderly: No dose adjustment
23. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity
24. Lack of pantoprazole drug interactions in man: An updated review
25. Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man
26. +-ATPase inhibitor pantoprazole